PARLIAMENTARY WRITTEN QUESTION
Leukaemia (2 May 2018)

To ask the Secretary of State for Health and Social Care, what assessment he has made of (a) the availability of current options for treatment on the NHS for patients with acute myeloid leukaemia and (b) the need for new options for treatment to be made available on the NHS in that area of disease.

Asked by:
Mark Tami (Labour)

In England there is a well-established framework for enabling access to cost effective new cancer medicines. All new licensed cancer medicines are referred to the National Institute for Health and Care Excellence (NICE) for inclusion within the Technology Appraisal Programme, this referral is irrespective of the clinical indication concerned. Where cancer medicines are approved by NICE for use in England, NHS England makes these available immediately. NICE now also has the ability to refer licensed medicines demonstrating promising, but not yet certain, benefits for inclusion within the Cancer Drugs Fund.

Answered by:
Steve Brine (Conservative)
14 May 2018